Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jean-Didier Rain is active.

Publication


Featured researches published by Jean-Didier Rain.


Journal of Clinical Oncology | 2011

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

Jean-Jacques Kiladjian; Sylvie Chevret; Christine Dosquet; Christine Chomienne; Jean-Didier Rain

PURPOSE The overall impact of hydroxyurea (HU) or pipobroman treatments on the long-term outcome of patients with polycythemia vera (PV) has not been assessed in randomized studies. We report final analyses from the French Polycythemia Study Group (FPSG) study, which randomly assigned HU versus pipobroman as first-line therapy in 285 patients younger than age 65 years. PATIENTS AND METHODS The full methodology has been described previously. FPSG results were updated with a median follow-up of 16.3 years. Statistical analysis was performed by using competing risks on the intention-to-treat population and according to main treatment received. RESULTS Median survival was 17 years for the whole cohort, 20.3 years for the HU arm, and 15.4 years for the pipobroman arm (P = .008) and differed significantly from that in the general population. At 10, 15, and 20 years, cumulative incidence of acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) was 6.6%, 16.5%, and 24% in the HU arm and 13%, 34%, and 52% in the pipobroman arm (P = .004). Cumulative myelofibrosis incidence at 10, 15, and 20 years according to main treatment received was 15%, 24%, and 32% with HU versus 5%, 10%, and 21% with pipobroman (P = .02). CONCLUSION Data from this unique randomized trial comparing HU with another cytoreductive drug in PV showed that (1) survival of patients with PV treated with conventional agents differed from survival in the general population, (2) evolution to AML/MDS is the first cause of death, (3) pipobroman is leukemogenic and is unsuitable for first-line therapy, and (4) incidence of evolution to AML/MDS with HU is higher than previously reported, although consideration should be given to the natural evolution of PV.


British Journal of Haematology | 1991

The site of platelet destruction in thrombocytopenic purpura as a predictive index of the efficacy of splenectomy

Y. Najean; V. Dufour; Jean-Didier Rain; M. E. Toubert

Summary The significance of the site of platelet sequestration in determining the indication for splenectomy in idiopathic thrombocytopenic purpura (ITP) is a controversial subject. However, most of the negative conclusions are based on 51chromium labelling of homologous platelets. We report here the results of an analysis of 222 cases in which the kinetic study of 111indium‐oxinate‐labelled autologous platelets was performed under homogeneous technical conditions. 103 of these patients subsequently underwent splenectomy.


Clinical Nuclear Medicine | 2001

Iodine-131 ablation therapy for a patient receiving peritoneal dialysis.

Marie-Elisabeth Toubert; Catherine Michel; Fabien Metivier; M. Can Peker; Jean-Didier Rain

The authors describe a patient with follicular thyroid carcinoma who was receiving continuous ambulatory peritoneal dialysis to manage end-stage renal disease. To deliver radioiodine therapy to ablate thyroid remnants safely and under optimal conditions, the behavior of 37 MBq (1 mCi) I-131 was followed daily for 3 days. Blood activity and total body count decreased with a half-life of 100 hours (4.17 days). The daily iodide removal rate, estimated as a percentage of the total administrated activity, was low: 5.3% to 8.6% in peritoneal dialysate and 1.3% to 2.2% in urine. The thyroid uptake, measured using a probe, was 2.4% to 2.1% from day 1 to day 3 and 1.9% later at day 8. The volume of thyroid remnants was determined by ultrasonography to be 0.6 g. The patient received a reduced ablative I-131 dose of 814 MBq (22 mCi). Radiation emitted from the patient after I-131 therapy, monitored using a radiation monitor probe located at a distance of 1 meter, decreased with an effective half-life of 70 hours (2.9 days). The integration of the curve from t = 0 showed a level always less than 25 &mgr;Sv/hour as early as 24 hours after treatment. Because the iodine removal rate is continuous but low in a case of peritoneal dialysis, smaller therapeutic doses must be administered to deliver maximal radiation to residual thyroid tissue while minimizing excessive radiation exposure to patients, their families, and medical staff.


Blood | 2005

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome

Corinne Haioun; Emmanuel Itti; Alain Rahmouni; Pauline Brice; Jean-Didier Rain; Karim Belhadj; Philippe Gaulard; Laurent Garderet; Eric Lepage; Felix Reyes; Michel Meignan


Blood | 1997

Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years

Yves Najean; Jean-Didier Rain


Blood | 2006

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

Jean-Jacques Kiladjian; Bruno Cassinat; Pascal Turlure; Nathalie Cambier; Murielle Roussel; Sylvia Bellucci; Marie-Laurence Menot; Gerald Massonnet; Jean-Luc Dutel; Kamel Ghomari; Philippe Rousselot; Marie-José Grange; Yasmina Chait; William Vainchenker; Nathalie Parquet; Lina Abdelkader-Aljassem; Jean-François Bernard; Jean-Didier Rain; Sylvie Chevret; Christine Chomienne; Pierre Fenaux


Blood | 1997

Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.

Yves Najean; Jean-Didier Rain


Blood | 2007

Increased adhesion to endothelial cells of erythrocytes from patients with Polycythemia Vera is mediated by laminin alpha5 chain and Lu/BCAM.

Marie-Paule Wautier; Wassim El Nemer; Pierre Gane; Jean-Didier Rain; Jean-Pierre Cartron; Yves Colin; Caroline Le Van Kim; Jean-Luc Wautier


Seminars in Thrombosis and Hemostasis | 2006

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

Jean-Jacques Kiladjian; Jean-Didier Rain; Jean-François Bernard; Jean Briere; Christine Chomienne; Pierre Fenaux


Blood | 2000

Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia

Bruno Cassinat; Philippe Guardiola; Sylvie Chevret; Marie-Helene Schlageter; Marie-Elisabeth Toubert; Jean-Didier Rain; Eliane Gluckman

Collaboration


Dive into the Jean-Didier Rain's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michel Meignan

Paris 12 Val de Marne University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alain Rahmouni

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar

Corinne Haioun

French Institute of Health and Medical Research

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge